Third chancellor finalist arrives on campus July 8

Robert Califf, M.D.

UNMC Chancellor finalist Robert Califf, M.D., will arrive on campus July 8.

Dr. Califf is the vice chancellor for clinical research and director of the Duke Translational Medicine Institute (DTMI) at the Duke University Medical Center.

Dr. Califf leads a multifaceted organization focused on the transformation of how discoveries are translated into improved health outcomes. Prior to his role at DTMI, he was the founding director of the Duke Clinical Research Institute (DCRI), a premier academic research organization.

See sidebar: Forum set for 4 p.m. Tuesday, July 9

He is the editor-in-chief of American Heart Journal, the oldest cardiovascular specialty journal.

Dr. Califf completed his undergraduate studies at Duke University in 1973, summa cum laude and Phi Beta Kappa, and later graduated from the Duke University Medical School.

Frederick Meyers, M.D.

After completing his internship and internal medicine residency at the University of California, San Francisco, he returned to Duke for a fellowship in cardiology. He is board-certified in internal medicine and cardiology.

Considered an international leader in the fields of cardiovascular disease treatment, health outcomes, quality of care, and medical economics, Dr. Califf is the author or coauthor of more than 1,000 peer-reviewed articles. The Institute for Scientific Information acknowledges him as one of the 10 most-cited authors in the field of medicine.

As director of DTMI, Dr. Califf’s contribution includes servicing as the first co-chair of the Principal Investigators Steering Committee of the NIH Clinical and Translational Science Award.

As the founder and director of DCRI, Dr. Califf led many landmark clinical trials in cardiovascular disease. Under his leadership, DCRI grew to an organization of more than 1,000 employees with an annual budget of more than $100 million.

Daniel Wilson, M.D., Ph.D.

A leader in clinical research, DCRI collaborates with government agencies, global academic partners, foundations and biotech, pharmaceutical, device, and diagnostics companies to execute clinical trials in a myriad of therapeutic arenas.

The three finalists are:

• Frederick Meyers, M.D., executive associate dean of the School of Medicine at the University of California, Davis;
• Daniel Wilson, M.D., Ph.D., the vice president for health affairs and dean of medicine at the University of Florida Health Science Center in Jacksonville; and
• Robert Califf, M.D., vice chancellor for clinical research and director of the Duke Translational Medicine Institute (DTMI) at the Duke University Medical Center.